Cargando…

Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study

Detalles Bibliográficos
Autores principales:	Mian, Hira, Sutradhar, Rinku, Pond, Gregory R., Sivapathasundaram, Branavan, Sussman, Jonathan, Balitsky, Amaris, D’Souza, Anita, Wildes, Tanya M., Seow, Hsien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795114/ https://www.ncbi.nlm.nih.gov/pubmed/35087029 http://dx.doi.org/10.1038/s41408-021-00602-4

Ejemplares similares

Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study
por: Mian, Hira S., et al.
Publicado: (2020)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

Artificial neural networks for simultaneously predicting the risk of multiple co‐occurring symptoms among patients with cancer
por: Xuyi, Wenhui, et al.
Publicado: (2020)

Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study
por: Mian, Hira, et al.
Publicado: (2023)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan
por: Cheng, Chih-Ning, et al.
Publicado: (2021)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
por: Mian, Owais, et al.
Publicado: (2023)

Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
por: Schoenbeck, Kelly L, et al.
Publicado: (2020)

Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis
por: Lyu, Wen-Wen, et al.
Publicado: (2016)

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma
por: Mian, Hira, et al.
Publicado: (2020)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
por: Puig, Noemi, et al.
Publicado: (2021)

Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With Cancer
por: Seow, Hsien, et al.
Publicado: (2020)

The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population‐based retrospective matched cohort analysis
por: Barbera, Lisa, et al.
Publicado: (2020)

Association between end-of-life cancer care and immigrant status: a retrospective cohort study in Ontario, Canada
por: Chu, Anna, et al.
Publicado: (2021)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia
por: Vukićević, Đurđa, et al.
Publicado: (2020)

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients
por: Djebbari, Faouzi, et al.
Publicado: (2020)

Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents
por: Nakaya, Aya, et al.
Publicado: (2017)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Benchmarking time to initiation of end-of-life homecare nursing: a population-based cancer cohort study in regions across Canada
por: Seow, Hsien, et al.
Publicado: (2018)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
por: Durie, Brian G. M., et al.
Publicado: (2020)

Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
por: Ocio, Enrique M., et al.
Publicado: (2023)

Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2023)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
por: Cook, Gordon, et al.
Publicado: (2019)

Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home Care
por: Seow, Hsien, et al.
Publicado: (2021)

Office-Based Laryngeal Biopsy in Patients Ineligible for General Anesthesia
por: Mozzanica, Francesco, et al.
Publicado: (2020)

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Characteristics and Outcomes of Patients Ineligible for Transcatheter Mitral Valve Replacement
por: Hatab, Taha, et al.
Publicado: (2023)

Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
por: Lee, Ho Sup, et al.
Publicado: (2013)

Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
por: Lu, Jin, et al.
Publicado: (2017)

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
por: Perrot, Aurore, et al.
Publicado: (2021)

Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis
por: Xie, Chunhong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5f5umjivcohvkgp760nb47ig46